Trial Profile
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms RESOLVE-1
- Sponsors Sunovion Pharmaceuticals
- 08 Feb 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
- 07 Aug 2018 Results published in the Journal of Clinical Psychiatry.
- 20 Sep 2016 Results of post hoc analysis evaluating the impact of baseline depression severity on treatment response presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.